| Followers | 23 |
| Posts | 2036 |
| Boards Moderated | 0 |
| Alias Born | 12/06/2017 |
Tuesday, January 24, 2023 3:16:00 PM
I just spoke with my son and he told me that CTXR if falling apart after he sold all our shares the other day. Wow this kid is getting better with his timing and taking the big profits. He will be getting a huge bonus- CTXR is down 15% today not a bad exit with a huge profit. O happy lunar new yr pp lol red is not a good look lol
Recent CTXR News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/22/2026 09:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:41:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:31:01 PM
- Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update • PR Newswire (US) • 05/15/2026 08:30:00 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update • PR Newswire (US) • 05/15/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 08:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 08:30:35 PM
- Citius Oncology Ships First International Order of LYMPHIR™ to Europe • PR Newswire (US) • 04/29/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 09:00:16 PM
- Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 04/24/2026 08:30:00 PM
- Citius Pharmaceuticals Secures $5M Through Equity Offering • IH Market News • 04/24/2026 02:48:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/24/2026 01:24:38 PM
- Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 04/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 08:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:32:33 PM
- Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development • PR Newswire (US) • 03/31/2026 01:11:00 PM
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts • PR Newswire (US) • 03/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 01:03:55 PM
- Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers • PR Newswire (US) • 03/10/2026 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 02:25:21 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/24/2026 01:04:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/24/2026 01:02:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/24/2026 01:00:41 PM
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program • PR Newswire (US) • 02/24/2026 01:00:00 PM
